【ann】評論
重新整理一下~(A)主要原因為隨著腎功能變差,EPO生成減少(B)治療目標為hemoglobin提升至11-12 g/dL (≧11 g/dL),以降低發生心血管疾病的風險及死亡率(D)接受erythropoietic-stimulating agents的病人,其體內鐵質含量目標為transferrin saturation20%以及ferritin100 ng/mL
【恩恩】評論
目前研究針對CKD造成的貧血,target Hb是 10
【蓉】評論
The strong recommendation not to aim for Hb increases to concentrations 13 g/dl is based on the interpretation of the combined results of the recent major RCTs showing more harm than benefit with higher Hb targets, as compared to lower Hb targets, including increased risks for stroke, hypertension, and vascular access thrombosis.Ref: KDIGO Clinical Practice Guidelinenfor Anemia in Chronic Kidney Disease 2012https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pd...
【加油】評論
洪太太為腹膜透析病人,她的hematocrit(Hct)值為 26.0%【題組】60. 根據美國腎臟基金會(K / DOQI)指引,合理的治療目標值應維持Hct為多少%? (A)30 (B)33 (C)35 (D)36 專技 - 藥物治療學- 103 年 - 103-1-藥師-藥物治療學#14228